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RÉSUMÉ  
L’arthrose (OA) est une maladie dégénérative et multifactorielle 
caractérisée par une destruction de cartilage, une formation d’ostéophytes et une 
inflammation au niveau de la membrane synoviale. Le 4-hydroxynonénal (HNE), 
un produit final de la peroxydation lipidique, a été identifié récemment comme un 
facteur catabolique et un médiateur inflammatoire dans le cartilage arthrosique 
humain. Notre projet vise à étudier l’effet du HNE sur la régulation de la 
prostaglandine E2 synthase-1 microsomale (mPGES-1) et de la protéine activante 
5-lipoxygénase (FLAP)/5-lipoxygénase (5-LOX) dans les chondrocytes 
arthrosiques humains. Lorsque les cellules sont traitées une seule fois avec 10 μM 
HNE, les résultats de Western blot et de PCR en temps réel montrent que 
l’expression de la cyclooxygénase-2 (COX-2) et de la mPGES-1 augmente de 
manière significative et atteint respectivement le maximum après 8 et 16 heures 
d’incubation puis diminue graduellement. Cependant, lorsque les cellules sont 
traitées plusieurs fois avec 10 μM HNE à 2 heures d’intervalle, l’expression de la 
COX-2 et de la mPGES-1 augmente en fonction du temps sans subir une baisse 
après 24 heures d’incubation. Le HNE induit l’activité du promoteur de la 
mPGES-1 via l’activation du facteur de transcription Egr-1. L’investigation de la 
2ème voie du métabolisme de l’acide arachidonique, à savoir 5-LOX/FLAP, montre 
que le HNE induit l’expression de FLAP après 24 heures de stimulation et celle de 
5-LOX seulement après 48 heures. Ceci semble survenir à l’étape de transcription 
au cours de laquelle HNE induit l’expression de l’ARNm et l’activité du 
 iv
promoteur du gène 5-LOX. Nous avons démontré aussi que le niveau de 
leukotriène B4 (LTB4) augmente et suit le même profil que celui de la 5-LOX. 
L’étude des mécanismes moléculaires susceptibles d’être impliqués dans la 
régulation de la 5-LOX/FLAP par le HNE montre que ce dernier stimule leur 
expression via l’action de prostaglandine E2 (PGE2) et du facteur de croissance 
transformant-beta 1 (TGF-β1). 
 
En conclusion, notre étude démontre que le HNE induit à court-terme 
d’incubation la voie de COX-2/mPGES-1 puis par la suite stimule celle de 
FLAP/5-LOX à long-terme d’incubation dans les chondrocytes arthrosiques 
humains. Ces résultats suggèrent que la mPGES-1 et 5-LOX/FLAP sont des 
potentielles cibles thérapeutiques intéressantes pour contrôler la production de 
PGE2 et LTB4 dans OA. 
 
Mots clés: 
Arthrose, Inflammation, Chondrocytes, Peroxydation lipidique, 4-hydroxynonénal, 
Cyclooxygénase-2, Prostaglandine E2 synthase-1 microsomale, Prostaglandine E2, 
5-lipoxygénase, Protéine activante 5-lipoxygénase, Leukotriène B4. 
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SUMMARY 
4-hydroxynonenal (HNE), a lipid peroxidation end-product, is produced 
abundantly in osteoarthritic (OA) articular tissues. Recently, we reported that 
HNE-induced cyclooxygenase-2 (COX-2) decreased gradually in human OA 
chondrocytes after 8 h of incubation. This study aimed to investigate whether 
COX-2 down-regulation is attributed to HNE depletion and is responsible for the 
switch from COX-2 to 5-lipoxygenase-activating protein (FLAP)/5-lipoxygenase 
(5-LOX). Treatment of chondrocytes with 10 µM HNE induced prostaglandin E2 
(PGE2) release as well as COX-2 and microsomal prostaglandin E2 synthase-1 
(mPGES-1) expression at the protein and mRNA levels, with a plateau reached at 
8-16 h of incubation, followed by a subsequent decline. However, 8 repeated 
treatments with 10 µM HNE prevented the reduction of COX-2 and mPGES-1 
expression. We demonstrated that HNE induced mPGES-1 promoter activity 
mainly through transcription factor Egr-1 activation. On the other hand, when 
COX-2 expression decreased, leukotriene B4 (LTB4) level rose after a long period 
of stimulation (48 and 72 h). At the mRNA level, HNE induced FLAP and 5-LOX 
expression after 24 and 48 h of stimulation, respectively. The addition of a 
nonspecific COX-2 inhibitor (naproxen) to cultured chondrocytes revealed that 
FLAP and 5-LOX regulation by HNE required PGE2 production. Furthermore, our 
data showed that 10 µM HNE significantly induced transforming growth factor-
beta 1 (TGF-β1) production. The addition of anti-TGF-β antibody to culture 
medium reduced HNE-induced 5-LOX/FLAP expression by 40%, indicating the 
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involvement of a TGF-β1-dependent mechanism. Our data demonstrate that the 
shunt to the FLAP/5-LOX pathway in HNE-induced human OA chondrocytes is 
attributed to COX-2 inhibition, probably due to HNE depletion. PGE2 and TGF-β1 
are suggested to be involved in this regulation. Further experiments are in progress 
to determine other molecular mechanisms underlying this switch in OA 
chondrocytes. 
 
Key words: 
Osteoarthritis, Inflammation, Chondrocytes, Lipid peroxidation, 4-hydroxynonenal, 
Cyclooxygenase-2, Microsomal prostaglandin E2 synthase-1, Prostaglandin E2, 5-
lipoxygenase, 5-lipoxygenase-activating protein, Leukotriene B4. 
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CHAPTER I: INTRODUCTION 
 2
1. SYNOVIAL JOINTS AND ARTICULAR CARTILAGE
Synovial joints are structures consisting of bone, hyaline cartilage, synovial 
membrane and joint capsule filled with synovial fluid (Fig. 1). Synovial fluid 
serves as a protective barrier by preventing contact between surfaces and provides 
nutrients to the hyaline cartilage (Schmidt et al., 2007). The latter covers the 
surface of bone and provides low-friction gliding surface with strong compressive 
strength and resistance; therefore it facilitates the movement of bones without 
difficulties and pain. Destruction of cartilage brings extreme pain during the 
movement, which we often see in osteoarthritis (OA) patients. In this section, we 
will discuss the structure, composition and biochemical characteristics of cartilage. 
 
1.1 Structure 
Morphologically, the hyaline cartilage is a connective tissue, which divides 
into four layers from the exterior to interior: superficial zone, transitional (middle 
zone), deep zone and calcified zone. The thickness of different layers depends on 
the inside component and the intensity of force applied (Poole et al., 2001). 
 
The superficial zone is the thinnest layer consisting of flattened cells 
aligned parallel to the surface. It is covered by the protein lubricin and synovial 
fluid. This parallel arrangement gives the greatest tensile strength to cartilage (Fig. 
2). The transitional zone of extracellular matrix (ECM) is formed by spheroid 
shaped cells with lower cell density and high concentration of 
 3
 
 
 
myDr, CMPMedica Australia, 2000-2009 
 
Figure 1: Structure of synovial joint 
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   (Poole et al., 2001) 
 
Figure 2: Structure of articular cartilage in adults 
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macromolecules, such as proteoglycans and collagens (Bhosale and Richardson, 
2008). 
 
Chondrocytes present in the deep zone have spheroid shape with 
perpendicular arrangement. Highest level of proteoglycan is observed in this zone. 
The calcified zone, the most profound zone of hyaline cartilage, contains low 
quantity of cells. However, the chondrocytes in this zone are special because they 
show hypertrophic phenotype and have capacity of synthesizing type V collagen 
(Col V) (Fig. 2). This feature provides an important structural integrity to the less 
elastic subchondral bone (Aigner and McKenna, 2002). 
 
1.2 Composition 
The hyaline cartilage is an avascular and alymphatic ECM composed of 
only chondrocytes. This ECM consists of 70% of water and 30% of collagen (Col), 
proteoglycan (PG) and elastic fibers. There exists many types of collagen 
including type II collagen (Col II), Col VI, Col IX, Col X and Col XI; among them 
Col II is the most abundantly present in ECM. These components help to maintain 
the tension and the movement of articulations as well as to provide essential 
nutrients for chondrocytes (Gardner, 1983;Bhosale and Richardson, 2008). 
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1.3 Metabolic and biochemical characteristics 
The characteristics of cartilage are determined by the structure and 
functions of molecules presenting in the ECM. Chondrocytes existing in the 
cartilage are very active and able to secrete various molecules such as cytokines, 
growth factors and enzymes. Interleukin-1 beta (IL-1β) and tumor necrosis factor 
alpha (TNF-α) produced abundantly by chondrocytes can generate different 
cellular responses through various signal pathways. For example, IL-1β stimulates 
inducible nitric oxide synthase (iNOS) expression through p38 Mitogen-activated 
protein kinases (MAPK) pathway (Badger et al., 1998). It can also stimulate 
nuclear factor-kappa B (NF-κB) that translocates to the nucleus to activate various 
genes. Furthermore, cyclooxygenase-2 (COX-2) and prostaglandin E2 (PGE2) 
synthesis were determined to be upregulated by IL-1β and TNF-α in explants of 
human OA knee menisci (LeGrand et al., 2001). 
 
As ECM is an avascular and alymphatic tissue, the transport of nutrients to 
chondrocytes is through diffusion. In normal cartilage, degradation (catabolism) 
and repair (anabolism) are in equilibrium, which is controlled by the synthesis of 
ECM components such as collagen, matrix metalloproteinases (MMPs) and tissue 
inhibitor of metalloproteinases (TIMP). In OA, catabolism is more active than 
anabolism. The overproduction of MMPs extensively degrades cartilage 
components, which cannot be repaired by anabolism mediator TIMP and results in 
OA (Fig. 3). 
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Figure 3: imbalance between anabolic factors (anti-inflammatory) and catabolic  
 factors (inflammatory), leading to the destruction of cartilage. 
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2. OSTEOARTHRITIS (OA) 
 
2.1 Definition and classification 
OA is the most common form of arthritis and one of the most pervasive 
diseases in the Western society. According to the Arthritis Society, approximately 
3 million Canadians suffer from OA. OA is a disease that affects a subset of the 
joints of the body, particularly the hips, knees and distal interphalangeal joints of 
the hands (Oliveria et al., 1995;Dieppe et al., 2002). Examination of an OA joint 
by arthroscopy or open surgery confirms a dramatic loss of articular cartilage 
(Gardner, 1983;Radin et al., 1991;Kerin et al., 2002). Histological examination of 
the cartilage confirms the gross anatomy and reveals a striking loss of ECM 
components (Poole, 1999;Felson et al., 2000). Depending on the region being 
examined, cartilage may be devoid of chondrocytes, presumably as a result of cell 
death, or contains clusters of chondrocytes that have undergone division, possibly 
in response to ECM depletion (Sandell and Aigner, 2001). Some chondrocytes 
appear to be synthesizing ECM at an elevated rate, as if attempting repair, while 
the synthetic rates of other chondrocytes are depressed (Haq et al., 2003). It is 
generally thought that an elevated ECM synthesis is a feature of early OA, while 
reduced synthetic rates occur later in the disease. Loss of articular cartilage is a 
progressive condition that develops in response to a variety of stimuli: mechanical 
or environmental, and is orchestrated by growth factors and cytokines acting 
through several signaling cascades (Radin et al., 1991;Pelletier et al., 1993;Arend 
and Dayer, 1995;Westacott and Sharif, 1996;Kerin et al., 2002). The cartilage 
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degradation is characterized by the loss of ECM components and qualitative 
changes of collagen. The precise mechanisms responsible for the initiation of 
cartilage degradation remain to be clarified. 
 
OA is classified into two groups: primary (idiopathic) and secondary. 
Primary OA is the most common form and has no known cause, although it is 
often related to aging and heredity. Secondary OA is related to antecedent factors 
including trauma, congenital or developmental diseases, metabolic diseases, 
endocrine diseases and other bone diseases.  
 
2.2 Epidemiology of OA 
2.2.1 Prevalence and incidence of OA 
OA is an extremely common joint disorder in the whole population. Its 
high prevalence and the frequency of OA-related physical disability make OA, 
especially in the elderly, one of the leading causes of disability. OA of the hip and 
knee represent two of the most significant causes of adult pain and physical 
disability. OA has a higher prevalence, and more often exhibits a generalized 
distribution in women than in men. Before the age of 50, men have a higher 
prevalence than women, but after the age of 50, women have a higher prevalence. 
This sex difference in prevalence further increases with age (Felson and Zhang, 
1998;Nevitt et al., 2001). Overall, OA occurs frequently in knees, hands, hips, 
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back, neck, wrists and ankles. Many people have joint symptoms without X-ray 
change and vice versa. 
 
2.2.2 Risk factors for OA 
Risk factors for OA include systemic and local biomechanical factors 
Systemic factors:  
Age, sex and ethnicity: the most potent systemic vulnerabilities are an increasing 
age and the female gender. Disease incidence and prevalence increase dramatically 
with age. The Framingham study found that 27% of those aged 63 to 70 had 
radiographic evidence of knee OA, increasing to 44% in the over 80 age group 
(Felson et al., 1995). Racial factor is another systemic factor with Asian people 
having very low rates of hip OA (Haq et al., 2003).  
 
Genetics: OA is a group of clinically heterogeneous disorders. Many genes have 
been linked to OA. There is most concordance with chromosomes 2q, 4 and 16. 
Families have been found with rare autosomal dominant patterns of inheritance of 
OA. The defective genes are often coding for structural proteins of the ECM of the 
joint and collagen (Haq et al., 2003;Gabay et al., 2008).  
 
Hormonal status: some women after age 50 develop “menopausal arthritis” at the 
time of menopause. These gender- and age-related prevalence patterns are 
consistent with a role for post-menopausal hormone deficiency in increasing the 
risk of OA. Estrogen loss has been strongly implicated as a risk factor. 
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Epidemiologic studies provide evidence that estrogen replacement therapy is 
associated with a reduction in the risk of knee and hip OA (Nevitt et al., 2001).  
 
Nutritional factors: people with lower vitamin C and vitamin D levels in blood 
have a threefold risk of progression of knee OA (Hunter et al., 2002). Vitamin C 
protects against damage by reactive oxygen species (ROS) and serves as a cofactor 
for enzymes contributing to Col II synthesis. Low dietary vitamin D intake 
increases the risk of knee OA progression (Bergink et al., 2009). 
 
Local biomechanical factors 
Obesity: many recent studies allow us to better understand the relationships 
between OA and obesity (Gabay et al., 2008). Although it is evident that 
mechanical components contribute to joint destruction in overweight people, OA is 
considered not only a disease of articular cartilage but also a systemic disorder in 
which circulating factors linked to altered lipid and glucose metabolism may 
explain the diversity of pathophysiological changes found in generalised OA. 
However, the potential contribution of adipose-derived cytokines in OA would not 
preclude the involvement of other mechanisms, including activation of 
mechanoreceptors and vascular dysfunction in the subchondral bone. 
 
Major joint injury: with a major joint injury, a person can sustain permanent 
damage of many of the structures within a joint. This damage alters its 
biomechanics, increases stress across particular areas of the joint and often 
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dramatically increases the risk of OA. The Framingham study found men with a 
history of knee injuries had a relative risk of 3.5 for subsequent knee OA; for 
women the relative risk was 2.2 (Felson, 1990). 
 
Occupational and athletic activities: OA is common in those performing heavy 
physical works, especially if this involves knees bending, squatting, or kneeling. 
Dockers and miners have been found to have a higher prevalence of knee OA than 
those in sedentary jobs (Partridge and Duthie, 1968). Epidemiologic study has 
demonstrated that participation in certain competitive sports increases the risk for 
OA (Buckwalter and Lane, 1997b). Sports activities that appear to increase the risk 
for OA include those that demand high-intensity, acute, direct joint impact as a 
result of contact with other participants, playing surfaces, or equipment 
(Buckwalter and Lane, 1997a). Repetitive joint impact and torsional loading also 
appear to be associated with joint degeneration.  
 
3. PATHOPHYSIOLOGY OF OA 
OA is one of the most frequent health problems for older people. It is a 
multifactorial degenerative joint disease characterized by the destruction of 
articular cartilage and synovial inflammation. The principal factors can be sex, 
gene, strenuous exercise, excess weight and injury (Hunter et al., 2002;Ouedraogo 
et al., 2008). The pathophysiology of OA is not completely understood, but its 
progression is being evaluated. The development of OA is usually separated into 
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three stages. Stage I is the imbalance between anabolic and catabolic metabolism, 
in which excessively synthesized proteases damage the cartilage matrix (Fig. 3). 
During stage II, the erosion of cartilage surface and inflammation of synovial 
membrane are observed, and the breakdown products are released into the synovial 
fluid. In stage III, these products are ingested by the synovial cells through 
phagocytosis, which is accompanied by the production of protease and 
proinflammatory cytokines (Martel-Pelletier, 2004). OA does not only cause the 
deterioration of cartilage but also the synovial membrane where an inflammatory 
reaction is often present. In this section, we will discuss the factors mediating in 
the development of OA, such as MMPs, aggrecanase protease, cytokines and ROS.    
 
3.1 Matrix metalloproteinases (MMPs) and aggrecanases 
MMPs are considered to be the main proteases responsible for proteolytic 
degradation of collagen and aggrecan in cartilage ECM (Martel-Pelletier et al., 
2001). The expression of several MMPs was elevated in synovial tissues of OA 
patients. Degradation of Col II in the matrix is an irreversible step in OA and it 
was thought to be catalyzed by the MMP-1. Newer evidences showed that MMP-
13 also has this effect and is the most reactive MMP in the degradation of OA 
cartilage. It targets Col II five times more rapidly than MMP-1 (Reboul et al., 
1996). More members of MMPs (MMP-3, MMP-8, MMP-14) were identified. 
MMP-3 and MMP-14 degrade proteoglycan and are involved in the activation of 
other pro-MMPs. All of these MMPs are able to degrade different types of 
 14
collagen with different extents and mechanisms (Moilanen et al., 2003). Several 
aggrecanases have been identified: A disintegrin and metalloprotease with 
thrombospondin motifs (ADAMTS)-1, ADAMTS-4 and ADAMTS-5. They are 
members of the ADAMTS family of aggrecanases. They degrade aggrecans during 
cartilage destruction (Nagase and Kashiwagi, 2003).  
 
3.2 Roles of cytokines in OA 
 Proinflammatory cytokines produced during synovial membrane 
inflammation upregulate MMPs gene expression and promote further progression 
of cartilage lesions in OA. They are synthesized by activated synoviocytes and by 
articular cartilage itself (Fernandes et al., 2002). Enhanced amounts of these 
mediators are found in OA synovial tissues compared to normal tissues. Among 
the cytokines, IL-1β and TNF-α are considered to be the principal mediators of 
joint destruction. It is evident that, in animal model experiments, inhibiting IL-1β 
synthesis and activity prevent cartilage damage, whereas blocking TNF-α reduces 
inflammation. This suggests that TNF-α drives inflammatory process and that IL-
1β is more responsible for cartilage destruction (Martel-Pelletier, 2004). The main 
action of IL-1β is to suppress proteoglycan and collagen synthesis in parallel with 
the release of destructive protease in chondrocytes. Other cytokines involved in the 
development of OA include IL-8, IL-17 and IL-6. It has been showed that IL-6 
deficient mice have a reduced joint inflammation (Van de Loo et al., 1997). These 
cytokines increase the number of inflammatory cells by upregulating other 
 15
proinflammatory cytokines, enhance the production of MMPs and stimulate the 
production of oxidative and inflammatory products synthesized by 5-lipoxygenase 
(5-LOX) (Guerne et al., 1989;Schroder, 1989). Use of specific anti-cytokine was 
found to reduce cartilage destruction in animal model; therefore, it was thought to 
be a treatment in the development of OA. 
 
Several anti-inflammatory cytokines (IL-4, IL-10 and IL-13) were also 
found at an increased level in synovial tissues. They have a protective role from 
the degradation of cartilage. They decrease the production of IL-1β, TNF-α and 
MMPs, upregulate TIMP-1 and inhibit PGE2 release (Hart et al., 1989;Jovanovic 
et al., 1998). Since IL-4 exerts its effect at the translational level and IL-10 at the 
transcriptional level, synergic protection was observed when these two cytokines 
are given as a combination therapy (Joosten et al., 1997). In this context, 
modulation of cytokines that control the gene expression of MMPs becomes the 
target for drug development in the treatment of OA.  
 
3.3 Reactive oxygen species (ROS) 
ROS are produced by chondrocytes and synoviocytes in response to 
mechanical stress and inflammatory mediators. Recently, ROS were found to be 
involved in the degradation of cartilage (Henrotin et al., 2003). The main ROS 
produced in OA are nitric oxide (NO) and superoxide anion (O2-). NO is 
synthesized mainly by iNOS enzyme. The production of NO is stimulated by IL-
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1β, TNF-α and lipopolysaccharides (LPS) and is inhibited by anti-inflammatory 
cytokines such as IL-4 and IL-10 (Stadler et al., 1991). In OA, an insufficient 
antioxidant capacity is not able to detoxify ROS; therefore oxidative stress will 
take place. Increased ROS induces chondrocyte apoptosis and cartilage matrix 
breakdown by upregulating the expression of MMPs (MMP-3 and MMP-13). It 
also modulates the production of pro-inflammatory mediators. However, some 
evidence had demonstrated that ROS are produced at a low level in chondrocytes 
and may contribute to the maintenance of cartilage homeostasis. It was observed 
that a decrease in levels of ROS reduces the ability of articular chondrocytes to 
regulate pH (Milner et al., 2007;Gibson et al., 2009).  
 
4. 4-HYDROXYNONENAL (HNE) 
4.1 Synthesis and characteristics of HNE 
 Oxidative stress initiates many signaling cascades of cellular functions 
including inflammation, cell proliferation and chemoattraction. Under oxidative 
stress, lipid peroxidation (LPO) of membrane polyunsaturated fatty acids proceeds 
through a free radical chain reaction to yield lipid peroxides. They are 
subsequently decomposed and generate several end products such as aldehydes.  
 
HNE was identified to be the most produced and cytotoxic aldehyde during 
lipid peroxidation. Due to its long half-life and α-β double bond, HNE can react 
easily with nucleic acids, proteins and phospholipids (Fig. 4). It also functions as a  
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    (Pappa et al., 2003) 
 
Figure 4: Structure of HNE with an α-β double bond and a hydroxyl group  
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bioactive molecule that affects numerous cell functions, including chemotactic 
activity, signaling transduction and gene expression (Esterbauer et al., 1991;Catala, 
2009). Increased level of HNE was found in plasma, various organs and cells 
under oxidative stress conditions and in many rheumatological diseases, such as 
liver damage and chronic lymphedema (Comporti, 1985;Poli et al., 1987;Siems et 
al., 2002). Therefore, HNE Michael adduct can serve as a biomarker for the 
presence of oxidative stress and tissue damage (Zarkovic, 2003). A previous study 
also demonstrated higher HNE concentration in synovial fluids and in 
chondrocytes of OA patients compared to normal subjects (Morquette et al., 2006). 
The topic of HNE recently became controversial because HNE was found to be a 
normal constituent of membrane in mammals, at low concentration, without 
toxicity. 
 
4.2 Metabolism of HNE 
A low level of HNE is normally present in mammalian cells. Obviously, 
organisms have several enzymatic pathways to detoxify HNE in order to protect 
proteins and lipids from damage by aldehydic products. The best characterized 
HNE-metabolizing enzymes include the glutathione-S-transferase (GST), aldose 
reductase, aldehyde dehydrogenase and alcohol dehydrogenase (Fig. 5) (Pappa et 
al., 2003). HNE can be modified to non-toxic products through the following 
reactions: 1) Michael addition of glutathione (GSH) to HNE to produce GS-HNE, 
2) the oxidation of HNE to 4-hydroxy-2-nonenoic acid (HNA), 3) the reduction to 
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unreactive 1,4-dihydroxy-2-nonene alcohol (DHN), 4) the interaction with 
carnosine, a dipeptide (beta-alanyl-L-histidine) present in high concentration in 
skeletal muscle (Aldini et al., 2002). Carnosine has numerous antioxidant 
properties and is able to scavenge ROS and unsaturated aldehydes formed during 
oxidative stress (Quinn et al., 1992;Babizhayev et al., 1994). Even with the rapid 
HNE metabolism, HNE-caused protein modification can occur. In different 
mammalian cells including hepatocytes, tumor cells and synovial fibroblasts, HNE 
metabolism is limited and a high level of protein-HNE adducts was observed  after 
the addition of HNE (Siems and Grune, 2003). These HNE-modified proteins are 
believed to be involved in many impaired cells-related diseases. In this context, the 
degradation of intracellular HNE becomes one important part of the antioxidative 
defense systems. 
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    (Modified from Pappa et al., 2003) 
Figure 5: Metabolism of HNE 
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4.3 HNE binding proteins 
HNE has a hydroxyl group and an α-β double bond, which make it highly 
reactive with specific amino acids of some proteins by the reaction of Michael 
addition to their particular functional groups. They were identified to be sulfhydryl 
group of cysteine, imidazole group of histidine and ε–amino group of lysine 
(Uchida and Stadtman, 1992a;Uchida and Stadtman, 1992b;Szweda et al., 1993). 
HNE can interact with many different cell proteins because it is quite stable and 
can pass through subcellular compartments. Several HNE-binding proteins were 
found, including glutamate transporter, proteasome and glyceraldehyde-3-
phosphate dehydrogenase (Blanc et al., 1998;Okada et al., 1999;Tsuchiya et al., 
2005). Due to its property of damaging DNA and proteins in cellular 
compartments, HNE was thought to be responsible for various pathophysiological 
effects associated with oxidative stress. 
 
4.4 HNE and signaling pathways 
Many studies suggested that HNE at low concentrations could be 
considered as a modulator of pathophysiological events by activating various 
signaling mechanisms, such as mitogen-activated protein kinases (MAPK), c-Jun 
N-terminal kinases (JNK) and caspase pathways. Apoptosis is one example of 
intracellular responses under oxidative stress in which caspases cascade is 
activated by HNE (Liu et al., 2000;Vaillancourt et al., 2008). Interestingly, 
increasing evidence showed that HNE stimulates the production of MMPs, 
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including MMP-2, MMP-9, and MMP-13 through ERK and p38 MAPK pathway 
in various cell types (Seo et al., 2010;Lee et al., 2010). HNE also induces COX-2 
expression through p38 MAPK (Fig. 6) (Kumagai et al., 2004). The roles of 
MMPs and inflammatory mediators in cartilage destruction have been extensively 
studied and defined. These findings suggest that HNE may be involved in the 
pathophysiology of OA in association with inflammatory responses.   
 
5. ARACHIDONIC ACID METABOLISM  
During its metabolism, arachidonic acid (AA) is released from hydrolysis 
of cell membrane phospholipids by cytosolic phospholipase A2 enzyme (cPLA2). 
AA is then oxygenated to form PGG2 by COXs, which subsequently reduce PGG2 
to the unstable intermediate called prostaglandin H2 (PGH2). PGH2 quickly 
transform to prostacyclins, thromboxanes and prostaglandins by prostaglandin E2 
synthase (PGES) (Smith et al., 2000;Park et al., 2006). Another AA metabolism 
pathway is catalyzed by 5-lipoxygenase-activating protein (FLAP)/5-lipoxygenase 
(5-LOX), which are the pivotal enzymes to yield leukotrienes (LTs) (Fig. 7). The 
amount of eicosanoid production is dependent on the release of AA by cPLA2 
(Park et al., 2006). The production and the regulation of these enzymes are 
discussed in detail in the following sections. 
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(Modified from Amgen Inc.) 
 
 
Figure 6: Role of HNE in the development of OA. 
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(Modified from Martel-Pelletier et al., 2003) 
 
 
Figure 7: Arachidonic acid metabolism 
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5.1 Cyclooxygenase (COX) 
Two COX isoforms have been identified: COX-1 and COX-2. They are 
encoded by different genes and expressed in different manners. COX-1 is a 
membrane-bound heme-containing glycoprotein expressed ubiquitously under 
normal conditions, whereas COX-2 is inducible and expressed by various stimuli 
(Martel-Pelletier et al., 2003;Uchida, 2008). Stimulation induces influx of calcium 
into the cell, leading to the translocation of cPLA2 from the cytosol to the nuclear 
membrane where it enzymatically hydrolyzes membrane phospholipids to liberate 
AA (Fig. 8) (Park et al., 2006). Different stimuli that can induce COX-2 
expression include pro-inflammatory IL-1β, TNF-α and growth factors, which 
promote prostaglandins synthesis and lead to further inflammation and 
carcinogenesis (FitzGerald, 2003). HNE was found to stimulate the expression of 
COX-2 and PGE2 production in chondrocytes, suggesting it may induce OA 
development through inflammatory processes (Vaillancourt et al., 2007).  
 
In human rheumatoid arthritis (RA) synovial membranes, immunostaining 
with anti-COX-2 antisera revealed the presence of COX-2 in infiltrating 
mononuclear cells, endothelial cells of blood vessels, and subsynovial fibroblast-
like cells. IL-1β and phorbol myristate acetate enhance de novo mRNA and protein 
synthesis of COX-2 in RA synovial membrane and cultured synovial fibroblasts. 
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         (Park et al., 2006) 
 
 
 
Figure 8: COX-2 expression in the absence or presence of stimulations 
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COX-2 is also expressed in cartilage specimens from OA patients (Amin et al., 
1997;Siegle et al., 1998). Osteoarthritic cartilage spontaneously releases PGE2 in 
levels at least 50-fold higher than the normal cartilage and 18-fold higher than 
normal cartilage stimulated with cytokines and endotoxin. The production of PGE2 
was sensitive to the translation inhibitor Cycloheximide, indicating the inducible 
aspect of this mediator. These observations indicate that COX-2 expression is 
upregulated in arthritic synovial membranes and cartilage, and suggest that 
selective inhibition of COX-2 may result in the amelioration of arthritic diseases. 
 
5.2 Prostaglandin E2 synthase (PGES) 
The terminal enzyme found in the COX pathway is called PGES, which 
collaborates with COX in the synthesis of prostaglandins from PGH2. Three 
isoforms of PGES have been determined: cytosolic PGES (cPGES), microsomal 
PGES-1 (mPGES-1) and mPGES-2. cPGES is preferentially coupled with COX-1 
to immediately produce PGE2, whereas mPGES-1 is inducible as COX-2, both 
work together to promote late synthesis of PGE2 (Fahmi, 2004). mPGES-2 is not 
well studied at present and its function is still unclear.  
 
At transcriptional level, mPGES-1 expression is regulated by 
transcriptional factors such as early growth response protein-1 (Egr-1) and nuclear 
factor-kappa B (NF-κB) (Cheng et al., 2004;Ackerman et al., 2008). The 
regulation of mPGES-1 by Egr-1 was found through two Egr-1 binding motifs 
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(tandem GC boxes) that are located in the proximal region of the mPGES-1 
promoter (Naraba et al., 2002;Subbaramaiah et al., 2004). On the other hand, 
mPGES-1 expression can be inhibited by a nuclear receptor called peroxisome 
proliferator-activated receptor gamma (PPARγ), which acts as a protector with 
anti-inflammatory and chondroprotective properties (Afif et al., 2007).  
 
Recently, the characteristics, regulations and roles of mPGES-1 in 
inflammation have been studied in various cells, including vein endothelial cells, 
chondrocytes, synoviocytes. mPGES-1 has been identified to be a membrane 
bound microsomal enzyme, which is induced by glutathione and upregulated by 
proinflammatory stimuli, such as IL-1β, TNF-α and LPS at both mRNA and 
protein level (Stichtenoth et al., 2001;Uracz et al., 2002;Kojima et al., 2004).  
 
5.3 Prostaglandin E2 (PGE2) 
PGE2 is an end product of AA through COX pathway. Its role as an 
inflammatory mediator is well known and its regulation mechanism is extensively 
studied. The group of Yucel-Lindberg investigated the effects of AA, PLA2 and 
PGE2 on the expression of mPGES-1 in fibroblasts. Interestingly, they found that 
cPLA2 inhibitors downregulated mPGES-1 expression, which is upregulated by 
the addition of AA and PGE2. These findings showed that the expression of 
mPGES-1 is regulated by PGE2 through positive feedback regulation, amount of 
AA and functional cPLA2 enzyme (Yucel-Lindberg et al., 2006). The effect of 
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PGE2 on the enhancement of mPGES expression was also found in synovial 
fibroblasts from patients with RA (Kojima et al., 2003). Another study showed 
that PGE2 has a regulatory function on the biosynthesis of leukotriene B4 (LTB4) 
and 5-LOX/FLAP expression. It decreases the production of LTB4 by inhibiting 
FLAP via IL-10 dependent mechanism in dendritic cells, but without any effect on 
5-LOX (Harizi et al., 2003). Recently, PGE2 produced by synovial COX-2 was 
shown to be involved not only in inflammation, but also in the modulation of the 
degradation of cartilage proteoglycan mediated by IL-1β (Hardy et al., 2002).  
 
5.4 5-lipoxygenase (5-LOX) 
5-LOX is a pivotal enzyme that catalyzes the first two steps in the 
biosynthesis of LTs, including LTB4 and cysteinyl-leukotrienes (cys-LTs). 5-LOX 
first catalyzes the conversion of AA to unstable epoxide intermediate LTA4, which 
is subsequently transformed to either LTB4 by LTA4 hydrolase or cys-LTs by 
LTA4 synthase (Fig 7). These LTs are pro-inflammatory lipids mediators that are 
involved in asthma, inflammation, allergy and phagocyte chemotaxis (Wardlaw et 
al., 1989;Bigby, 1999).  
 
5.5 Regulation of 5-LOX expression 
5-LOX contains a large catalytic domain consisting of a non-heme iron 
atom and an ATP binding site, which are crucial for the catalytic potential of 5-
LOX (Aparoy et al., 2008). Calcium and ATP are two important factors that 
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influence 5-LOX activation. In an environment without these two factors, the 
enzyme activity of 5-LOX is limited, but can be recovered by the addition of Ca2+ 
(Rouzer and Samuelsson, 1987). Interestingly, the increase in 5-LOX activity by 
ATP only happens in the presence of Ca2+ (Noguchi et al., 1996). Ca2+ plays an 
important role in the movement of 5-LOX to the nuclear membrane, allowing its 
binding with FLAP. 
 
5-LOX is highly expressed in leukocytes, cancer cells and especially in 
differentiated cells. The expressions of 5-LOX mRNA and protein are induced by 
transforming growth factor-beta 1 (TGF-β1) and dihydroxyvitamin D3, DMSO and 
granulocyte/macrophage colony-stimulating factor (GM-CSF) in human 
monocytic Mono Mac 6, leukemia HL-60 cells and granulocytes (Krump and 
Borgeat, 1994;Brungs et al., 1994). These findings suggested that TGF-β1, 
dihydroxyvitamin D3 and GM-CSF act as differentiation inducers and promote 5-
LOX synthesis in various cells (Krump and Borgeat, 1994;Harle et al., 1999). 5-
LOX transcription activity increases when 5-LOX promoter construct is 
cotransfected with Egr-1 expression vector (Cheng et al., 2004). The transcription 
factor Egr-1 binds to GC sequences and interacts with transcriptional coactivators. 
This indicates that inducible 5-LOX gene transcription is mediated by Egr-1 and 
maybe by other transcriptional factors in GC rich promoter region (Silverman et 
al., 1998). 5-LOX expression can also be stimulated by dihydroxyvitamin D3, 
which is synthesized in synovial fluid of patients with inflammatory arthritis. In 
OA cartilage, Tetlow and Woolley indicated that 5-LOX promoter contains a 
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vitamin D receptor element (VDRE), which induces 5-LOX expression by 
interaction with vitamin D receptors (VDR) (Tetlow and Woolley, 2001). 
 
5.6 5-lipoxygenase-activating protein (FLAP) 
FLAP is a nuclear membrane bound protein that collaborates with 5-LOX. 
When cells are stimulated, cPLA2 and 5-LOX migrate to the nuclear membrane. 
FLAP helps the binding of 5-LOX with AA and the efficient utilization of AA 
released from phospholipids, leading to the biosynthesis of LTs (Fig. 9) (Murphy 
and Gijon, 2007). It has been shown that transformation of AA by 5-LOX is 
efficiently blocked in cells missing FLAP. Even FLAP is required for the LTs 
biosynthesis from endogenous AA, but metabolism of exogenous AA does not 
need FLAP. 
 
This observation suggests that FLAP is not mandatory but can facilitate 
and enhance 5-LOX activity (Coffey et al., 1994). Furthermore, the expression of 
5-LOX and FLAP as well as LTB4 synthesis are enhanced in various inflammatory 
conditions, such as OA, systemic sclerosis and asthma (Chu et al., 2000;Kowal-
Bielecka et al., 2001;Lascelles et al., 2009).  
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             (Murphy RC, 2007) 
 
Figure 9: Intracellular organization of the critical enzymes involved in leukotriene  
    biosynthesis  
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6. OBJECTIVES AND HYPOTHESIS 
Recently, we reported that the induction of COX-2 decreased dramatically 
after 8 hours of incubation with HNE, an end product of lipid peroxidation. HNE 
was thought to be involved in the pathophysiology of OA due to its ability to 
induce the expression of MMP-13 and COX-2, leading to destruction of cartilage 
and synovial inflammation. This study aimed to investigate the regulation of 
mPGES-1, FLAP and 5-LOX expression by HNE as well as the biosynthesis of 
PGE2 and LTB4 in human OA chondrocytes with different periods of incubation. 
We hypothesize that COX-2 and mPGES-1 down-regulation is attributed to HNE 
depletion and is responsible for the switch from COX-2 to FLAP/5-LOX pathway, 
resulting in the decrease of PGE2 production and an increase of LTB4. It has been 
shown that there is a switch of COX pathway to FLAP/5-LOX in the presence of 
low PGE2. This study is also to investigate the involvement of transforming 
growth factor-beta 1 (TGF-β1) in this switch. In addition, increased LTB4 level in 
synovial tissues was observed in OA patients who usually take COX-2 inhibitors. 
Therefore, our hypothesis is that HNE may be involved in the switch from COX-2 
to FLAP/LOX pathway in human OA chondrocytes.  
 34
 
 
 
 
 
 
 
CHAPTER II:  
MATERIALS AND METHODS 
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Specimen selection and chondrocyte culture 
Human OA articular cartilage was obtained from OA patients aged 67 ± 9 
years (mean ± SD) who underwent total knee arthroplasty. Informed consent had 
been obtained from patients with OA for the use of their tissues for research 
purposes. All patients were evaluated by rheumatologists who followed American 
College of Rheumatology criteria (Altman et al., 1986). The experimental protocol 
and use of human tissues were approved by the Research Ethics Board of Hôpital 
du Sacré-Cœur de Montréal. OA cartilage (femoral condyles and tibial plateaus) 
was obtained under aseptic conditions and carefully dissected from the underlying 
bone in each specimen (Benderdour et al., 2002). OA chondrocytes were extracted 
by sequential enzymatic digestion  with 1 mg/ml of pronase (Sigma, Oakville, 
Ontario, Canada) for 1 h at 37ºC, then with 2 mg/ml of type IV collagenase (Sigma) 
for 6 h in Dulbecco’s modified Eagle’s medium (DMEM; Gibco BRL, Burlington, 
Ontario, Canada) supplemented with 10% heat-inactivated fetal bovine serum 
(FBS; Invitrogen Life Technology, Inc., Grand Island, NY, USA), 100 units/ml of 
penicillin and 100 µg/ml of streptomycin (Invitrogen Life Technology, Inc.). The 
cells were seeded at high density in culture flasks at 37ºC in a humidified 
atmosphere of 5% CO2/95% air until they were confluent and ready for the 
experiments. First-passage cells were employed to ensure their phenotype and 
seeded at 105 cells/cm2 in culture tissue plates. The DMEM containing 2% FBS 
and antibiotics was replaced 24 h before the experiments were performed in this 
medium with the factors under study for different incubation time periods. 
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Chondrocytes were treated with single addition of 10 µM HNE for increasing 
times (0 to 72 h) or with repeated treatments by adding 10 µM HNE to the cultures 
at t=2, 4, 6, 8, 10, 12, 16, 24 h. For drug exposure, cells were pre-treated with 50 
µM naproxen or 100 µg/ml anti-transforming growth factor-beta 1 (TGF-β1) 
antibody for 1 h, followed by a second incubation for 24 or 72 h in the presence or 
absence of 10 µM HNE.  
 
Protein detection by Western blotting 
Twenty micrograms of total proteins from chondrocyte lysates treated with 
HNE under the indicated conditions were loaded for discontinuous 4-12% sodium 
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). Protein transfer 
and immunodetection as well as semi-quantitative measurements were performed 
as described previously (Morquette et al., 2006). The primary antibodies were 
rabbit anti-COX-2, anti-mPGES-1 (Cayman Chemical-Cedarlane, Hornby, Ontario, 
Canada), anti-β-actin and anti-Egr-1 (Santa Cruz Biotechnology, Santa Cruz, CA, 
USA). After serial washes, primary antibodies were detected by goat anti-rabbit 
immunoglobulin G conjugated to horseradish peroxidase (Jackson 
ImmunoResearch Laboratories, Inc., West Grove, PA, USA). Immunoreactive 
proteins were detected with SuperSignal blotting substrate (Pierce Biotechnology, 
Inc., Rockford, IL, USA) and exposed to clear-blue x-ray film (Pierce). 
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RNA extraction and reverse transcription-polymerase chain 
reaction (RT-PCR)  
Total RNA was isolated with TRIzol reagent according to the 
manufacturer's instructions. RNA was quantitated with RiboGreen RNA 
quantitation kit (Molecular Probes, Eugene, OR, USA), dissolved in 
diethylpyrocarbonate-treated H2O, and stored at -80°C until used. One microgram 
of total RNA was reverse-transcribed with Moloney murine leukemia virus reverse 
transcriptase (Fermentas, Burlington, Ontario, Canada), as detailed in the 
manufacturer's guidelines. One-fiftieth of the reverse transcriptase reaction product 
was analyzed by traditional PCR or real-time quantitative PCR. The following 
sense and antisense specific primers (purchased from Bio-Corp, Inc., Montreal, 
Quebec, Canada), were tested: human mPGES-1, 5’-GAA GAA GGC CTT TGC 
CAA C-3’ (sense) and 5’-GGA AGA CCA GGA AGT GCA TC-3’ (antisense); 
human 5-LOX, 5’-CTG TTC CTG GGC ATG TAC CC-3’ (sense) and 5’-GAC 
ATC TAT CAG TGG TCG TG-3’ (antisense); human FLAP, 5’-AAT GGG AGG 
AGC TTC CAG AG-3’ (sense) and 5’-ACC AAC CCC ATA TTC AGC AG-3’ 
(antisense); human GAPDH, 5’-CAG AAC ATC ATC CCT GCC TCT-3’ (sense) 
and 5’GCT TGA CAA AGT GGT CGT TGA G-3’ (antisense).  
 
Quantitative PCR analysis was performed in a total volume of 50 µl 
containing template DNA, 200 nM sense and antisense primers, 25 µl of SYBR 
Green Master Mix (Qiagen, Mississauga, Ontario, Canada), and 0.5 units of uracil-
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N-glycosylase (UNG; Epicentre Technologies, Madison, WI, USA). After 
incubation at 50°C for 2 min (UNG reaction) and at 95°C for 10 min (UNG 
inactivation and activation of AmpliTaq Gold enzyme), the mixtures were 
subjected to 40 amplification cycles (15 s at 95°C for denaturation and 1 min for 
annealing and extension at 60°C). Incorporation of SYBR Green dye into the PCR 
products was monitored in real time with a Mx3000 real-time PCR systems 
(Stratagene, La Jolla, CA, USA), to determine the threshold cycle (Ct) at which 
exponential amplification of PCR products begins. After PCR, dissociation curves 
were generated with 1 peak, indicating amplification specificity. A Ct value was 
obtained from each amplification curve with the software provided by the 
manufacturer (Stratagene). 
 
Relative mRNA expression in chondrocytes was quantified according to 
the ΔΔCt method, as detailed in the manufacturer's guidelines (Stratagene). A ΔCt 
value was first calculated by subtracting the Ct value for the housekeeping gene 
GAPDH from the Ct value for each sample. A ΔΔCt value was then calculated by 
subtracting the ΔCt value for the controls (unstimulated cells) from the ΔCt value 
for each treatment. Fold changes compared with the controls were then determined 
by 2-ΔΔCt. Each PCR generated only the expected specific amplicon, as shown by 
melting temperature profiles of the final product and gel electrophoresis of the test 
PCRs. Each PCR was performed in triplicate on 2 separate occasions for each 
independent experiment. 
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PGE2, LTB4 and transforming growth factor-beta 1 (TGF-β1 
enzyme immunoassay 
After incubation, the culture medium from cultured OA chondrocytes was 
collected and PGE2 and LTB4 levels were measured with specific commercial kits 
for PGE2 (Cayman Chemical), LTB4 and TGF-β1 (R&D Systems, Minneapolis, 
MN, USA), according to the manufacturer’s instructions. Detection sensitivity was 
9, 13.7, 4.6 pg/ml, respectively. All assays were in triplicate. 
 
Plasmids and transient transfection 
The human mPGES-1 promoter construct (-538/-28) was a gift from Dr. 
Terry J. Smith (University of California, Los Angeles, CA, USA) (Han et al., 
2002). The pEgr-1Mutx3-TK-Luc reporter construct was generously provided by 
Dr. Yuqing E. Chen (Morehouse School of Medicine, Atlanta, GA, USA) (Fu et 
al., 2002). The 5-LOX promoter construct was kindly donated by Dr. Dieter 
Steinhilber (University of Frankfurt, Frankfurt, Germany). Subconfluent human 
OA chondrocytes were transiently transfected in 12-well cluster plates with 
lipofectamine 2000TM reagents (Invitrogen Life Technology, Inc.), according to 
the manufacturer's protocol. Briefly, transfections were conducted for 6 h with 
DNA lipofectamine complexes containing 10 µl of lipofectamine reagent, 2 µg 
DNA plasmid and 0.5 µg of pCMV-β-gal (as a transfection efficiency control). 
After washing, the cells were stimulated with 10 µM HNE for different incubation 
periods, depending on the experiments. Luciferase activity was determined in 
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cellular extracts with commercially-available kits (Luciferase assay system, 
Promega Corporation, Madison, WI, USA). The data were normalized to β-gal 
level, which was quantified by a specific ELISA (Roche Applied Science, Laval, 
Quebec, Canada). 
 
Statistical analysis  
For the time course experiments, all quantitative results were expressed as 
means ± SEM. The data were compared by ANOVA. p values less than 0.05 were 
considered to be statistically significant and contrast tests were against the control 
(time = 0 h). Two-way ANOVA was used to analyze the results from the 
experiments with treatments of two factors, such as HNE and naproxen or HNE 
and TGF-β1. Their interaction and main effects are reported in the figures. 
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CHAPTER III: RESULTS 
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Single or repeated treatments with HNE regulate differently PGE2 
release and COX-2 protein expression 
As described in our previous report, COX-2 expression decreased 
gradually after 8 h of chondrocyte incubation with 10 μM HNE. To examine 
whether this reduction is attributable to HNE depletion, cells were stimulated with 
either one or repeated 10 μM HNE treatments for different incubation periods (0 to 
24 h, n = 3 independent experiments). Chondrocyte stimulation with 10 μM HNE 
(1 treatment) showed that COX-2 protein expression and PGE2 release increased 
within 4 h and plateaued at 8 h of incubation, before declining at 16 and 24 h (Fig. 
1A & 1C). PGE2 and COX-2 reached maximum levels of 157.5 ± 33 ng/105 cells 
and 340% of control values, respectively. However, in experiments where the cells 
were stimulated repeatedly, COX-2 expression and PGE2 release were enhanced 
after 4 h and 8 h of incubation respectively, with maximum values obtained at 24 h 
(Fig. 1B & 1D). Maximum PGE2 and COX-2 values were 210 ± 29 ng/105 cells 
and 400% of control values, respectively. HNE was cytotoxic at >20 μM and 
significantly decreased cell viability (data not included). 
 
Induction of mPGES-1 protein and mRNA expression by single or 
repeated treatment with HNE 
To gain insights into the role of HNE in the modulation of mPGES-1, the 
inducible form of PGES involved in the terminal step of PGE2 synthesis, we 
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Figure 10. HNE-induced PGE2 production and COX-2 expression in 
human OA chondrocytes  
Cells were stimulated once (A & C) or repeatedly (B & D) with 10 µM HNE every 
2 h for different incubation periods, as indicated above. PGE2 concentration (A & 
B) was measured by enzyme immunoassay (EIA) commercial kit. COX-2 protein 
expression (C & D) was analyzed by Western blotting. The data are means ± SEM 
of n = 3 and contrast test is against the control (time = 0 h). The significance was 
calculated by ANOVA: * p < 0.05.  
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evaluated its effect on the expression of this enzyme in human OA chondrocytes 
treated once or several times for different incubation periods (n = 3 independent 
experiments). As depicted in Figures 2A and 2C, one treatment with 10 µM HNE 
significantly increased mPGES-1 protein and mRNA levels, which plateaued at 16 
h but then declined at 24 h. mPGES-1 protein and mRNA reached maximum 
levels of 230 and 214% of control values, respectively. However, repeated 
treatments with 10 µM HNE enhanced mPGES-1 protein and mRNA levels, with 
maximum value attained at 24 h (Fig. 2B and 2C). The maximum levels of 
mPGES-1 protein and mRNA were 430 and 300% of the controls, respectively. 
 
HNE-induced mPGES-1 and 3xEgr-1 binding site promoter 
activities 
In our previous report, we have reported that HNE induced COX-2 
transcription through ATF-2/CREB-1 transactivation (Vaillancourt et al., 2007). In 
the present study, we further examined whether HNE induced mPGES-1 at 
transcriptional level through Egr-1 transactivation. Firstly, to determine whether 
changes in mPGES-1 mRNA levels can be ascribed to alteration in promoter 
activity, chondrocytes were transiently transfected with human mPGES-1 
promoter-luciferase reporter genes (n = 3 independent experiments). Treatment of 
transfected cells with 10 µM HNE for increasing periods of incubation led to a 
time-dependent increment of mPGES-1 promoter activity (Fig. 3A). Maximum 
promoter activity was 331% at 16 h compared to the controls. These data are 
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Figure 11. HNE-induced mPGES-1 protein and mRNA expression in human 
OA chondrocytes 
Cells were stimulated with 10 µM HNE once (A & C) or repeatedly (B & C) with 
10 µM HNE every 2 h for different incubation periods, as indicated above. 
mPGES-1 protein (A & B) and mRNA (C) were measured respectively by 
Western blotting and real-time RT-PCR. The data are means ± SEM of n = 3 and 
contrast test is against the control (time = 0 h). The significance was calculated by 
ANOVA: * p < 0.05. 
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Figure 12. HNE-activated mPGES-1 promoter 
Chondrocytes were transfected with mPGES-1-Luc (A) or p3xEgr-1-Luc (B) 
containing 3 Egr-1 binding sites. The next day, they were incubated with 10 µM 
HNE for increasing incubation time periods. Luciferase activity was measured in 
cell extracts and normalized to β-galactosidase activity. (C) OA chondrocytes were 
treated with 10 µM HNE at increasing time of incubation and then Egr-1 protein 
expression was evaluated in cellular extract by Western blot. The data are means ± 
SEM of n = 3 and contrast test is against the control (time = 0 h). The significance 
was calculated by ANOVA: * p < 0.05. 
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consistent with the regulation of mPGES-1 expression by HNE at the transcription 
level. The transcription factor Egr-1 has been shown to play a crucial role in 
mPGES-1 transcription. Therefore, we analyzed the effect of HNE on the 
transcriptional activation of a synthetic luciferase reporter construct containing 3 
tandem repeats of the putative Egr-1 binding sequence pEgr-1×3-TK-Luc. As seen 
in Figure 3B, HNE increased luciferase activity of the above construct, and this 
activation was time-dependent. Maximum promoter activity reached 450% at 16 h 
compared to the controls (Fig. 3B). Western blot analysis revealed that single 
treatment with 10 µM HNE induced Egr-1 protein expression by 280% compared 
to untreated cells after 16 h of incubation (Fig. 3C). Collectively, these data 
suggest that Egr-1 may be one of the transcription factors involved in HNE-
induced mPGES-1 promoter activity. 
 
HNE-induced LTB4 release through 5-LOX and FLAP up-
regulation 
LTB4 is an end product of an inflammatory signaling pathway. It has been 
found to regulate the synthesis of other catabolic factors involved in the 
pathophysiology of OA (Martel-Pelletier et al., 2004). Human OA chondrocytes (n 
= 5 independent experiments) were stimulated with 10 μM HNE for different 
incubation periods. HNE-induced changes in LTB4 level was measured with EIA 
commercial kits. LTB4 release (Fig. 4A) was induced only after 48 h incubation 
period, with a further increase after 72 h of treatment (66.6 ± 3.7 pg/105 cells). 
 51
 
 
Figure 13 
 
     A             B 
0 8 16 24 48 72
0
20
40
60
80
*
*
Time of incubation (h)
LT
B
4 
le
ve
ls
(p
g/
10
5  
ce
lls
)
 
0 8 16 24 48 72
0
200
400
600
800
1000
*
*
*
Time of incubation (h)
FL
AP
 m
R
N
A 
ex
pr
es
si
on
(%
 o
f c
on
tr
ol
 )
 
                C 
         
0 8 16 24 48 72
0
200
400
600
800
 *
  *
Time of incubation (h)
5-
LO
X 
m
R
N
A 
ex
pr
es
si
on
(%
 o
f c
on
tr
ol
)
 
 
Figure 13. HNE-induced LTB4 biosynthesis and 5-LOX and FLAP mRNA 
expression in human OA chondrocytes 
Cells were treated with 10 µM of HNE for different incubation time periods, as 
indicated above. LTB4 production (A) was evaluated by EIA commercial kit. 
FLAP (B) and 5-LOX (C) mRNA expression was measured by real-time RT-
PCR. The data are means ± SEM of n = 5 and contrast test is against the control 
(time = 0 h). The significance was calculated by ANOVA: * p < 0.05. 
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5-LOX and FLAP are essential proteins responsible for LTB4 synthesis. To 
determine whether augmented LTB4 production induced by HNE is related to 5-
LOX and FLAP synthesis, we further examined the effect of HNE on their mRNA 
expression. As shown in Figures 4B and 4C, our data disclosed that both FLAP 
and 5-LOX mRNA expression rose significantly but differentially after incubation 
in human OA chondrocytes. FLAP mRNA expression occurred earlier, after 24 h 
of incubation, compared to 5-LOX (48 h). Maximum FLAP and 5-LOX levels 
were 644% and 566% of control values, respectively. 
 
HNE-induced 5-LOX promoter activity 
To more accurately identify whether HNE-induced 5-LOX at the 
transcription level, the 5-LOX promoter construct with luciferase gene reporter 
was transiently transfected into human OA chondrocytes, followed by stimulation 
with 10 μM HNE (n = 3 independent experiments). Compared to unstimulated 
cells, HNE induced 5-LOX gene promoter activity in transfected chondrocytes. 5-
LOX promoter activity increased significantly by 310% and 580% after 48 and 72 
h of incubation, respectively (Fig. 5). These data indicated that HNE regulates 5-
LOX mRNA expression at transcriptional level. 
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Figure 14. HNE-activated 5-LOX promoter in human OA chondrocytes 
Cells were transfected with human 5-LOX promoter. The next day, they were 
incubated with 10 µM HNE for increasing incubation time periods. Luciferase 
activity was measured in cell extracts and normalized to β-galactosidase activity. 
The data are means ± SEM of n = 3 and contrast test is against the control (time = 
0 h). The significance was calculated by ANOVA: * p < 0.05. 
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Effect of COX inhibition on FLAP and 5-LOX expression  
Further experiments were aimed at elucidating the role of PGE2 in HNE-
induced 5-LOX and FLAP expression in OA chondrocytes. Firstly, cells were 
treated with 50 μM naproxen (a non-selective COX inhibitor) for 1 h followed by 
another treatment of 10 μM HNE for 24 or 72 h (n = 3 independent experiments). 
Our real-time RT-PCR results demonstrated that HNE induced FLAP expression 
after 24 h of treatment (210% of control) and the level was even higher after 72 h 
(315% of control) (Fig. 6A and 6B). In contrast, FLAP expression was diminished 
by naproxen after 24 and 72 h (75% of control). HNE-induced FLAP expression 
was also abolished by naproxen, which prevents PGE2 production. HNE did not 
induce 5-LOX expression after 24 h of incubation. It stimulated 5-LOX expression 
only after 72 h by 600% above control values (Fig. 6D). However, incubation of 
cells with naproxen caused a consistent increase of 5-LOX mRNA level by 330% 
and 570% of control values after 24 and 72 h of incubation, respectively (Fig. 6C 
& 6D). We observed that PGE2 has different effects on the expression of FLAP 
and 5-LOX. It has been indicated that the inhibition of PGE2 up-regulates 5-LOX 
while down-regulating FLAP gene expression (Martel-Pelletier et al., 2004). We 
showed that the production of PGE2 during 24 h of HNE incubation prevents 5-
LOX expression. However, between 24 and 72 h, the level of PGE2 (35 ± 15 
(control) vs. 55 ± 21 (72 h), not significant) was low due to the decrease in COX-2 
expression, which allows 5-LOX to be expressed (Fig. 4C). All these data suggest 
that PGE2 has opposite effects on 5-LOX and FLAP regulation by HNE.   
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Figure 15. HNE-induced FLAP/5-LOX expression is PGE2-dependent in 
human OA chondrocytes 
Cells were treated with 50 µM naproxen, 10 µM HNE or both for 24 or 72 h. 
FLAP (A & B) and 5-LOX (C & D) mRNA expression was evaluated by real-time 
RT-PCR. The data are means ± SEM of n = 3 and contrast test is against the 
control (time = 0 h). The significance was calculated by ANOVA. 
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HNE induction of 5-LOX/FLAP mRNA is TGF-β1-dependent 
In other experiments, we determined whether TGF-β1 production could be 
involved in HNE-induced 5-LOX/FLAP expression. Chondrocytes were treated or 
not with 10 μM HNE for 72 h in the presence or absence of 100 µg/ml of TGF-β1 
antibody. As illustrated in Figure 7, 10 μM HNE elevated TGF-β1 levels in 
chondrocyte culture media (n = 3 independent experiments) to 210, 288 and 201 
pg/ml at 24, 48, 72 h of incubation respectively. Interestingly, the addition of anti-
TGF-β1 antibody (TGF-β1 neutralization) to cultured cells attenuated HNE-
induced 5-LOX and FLAP by 50-65%, from 255% to 175% for 5-LOX mRNA 
and from 286% to 167% for FLAP mRNA expression. It has been showed that 
TGF-β1 induced a marked enhancement in FLAP and 5-LOX mRNA levels 
(Martel-Pelletier et al., 2004). Our data suggest that 5-LOX and FLAP regulation 
by HNE is partially mediated via TGF-β1 production.  
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Figure 16. HNE-induced FLAP/5-LOX expression is TGF-β1-dependent in 
human OA chondrocytes 
TGF-β1 level (A) was measured with ELISA commercial kits and expressed as 
pg/ml. (B & C) Cells were treated with 10 µM HNE for 72 h in the presence or 
absence of anti-TGF-β1 antibody, 5-LOX and FLAP mRNA levels were then 
assessed by real-time RT-PCR. The data are means ± SEM of n = 3 and contrast 
test is against the control (time = 0 h). The significance was calculated by 
ANOVA: * p < 0.05. 
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CHAPTER IV: DISCUSSION 
 61
HNE: A pathophysiological modulator 
Numerous studies have shown that oxidative stress was involved in the 
pathophysiology of OA, caused by the excessive production of ROS and an 
insufficient availability of antioxidants to detoxify ROS (Chen et al., 2008;Davies 
et al., 2008;Roman-Blas et al., 2009). ROS induces LPO of membrane 
polyunsaturated fatty acids, leading to the production of aldehydes from AA. 
Similar to free radicals, aldehydes are eletrophiles that bind to the nucleophilic 
groups of proteins, (amino)phospholipids and nucleic acids, but their relatively 
longer half-life made them candidates for the propagation of damage to 
neighbouring cells. Among the aldehydes, HNE is considered to be the most 
reactive species because of its α,β-double bond, which make HNE more 
susceptible to nucleophilic attack (Uchida, 2003). Whether aldehydes are “second 
toxic messengers”, as first hypothesized by Esterbauer (Esterbauer et al., 1991), or 
merely represent changed markers of extensive tissue damage (Halliwell and 
Chirico, 1993), has long been a subject of controversies. This situation recently 
changed, when HNE was found to be a normal constituent of mammalian tissue 
membranes (Poli et al., 2008). One specific property of HNE is its ability to bind 
to proteins. The α,β-double bond of HNE reacts readily with specific amino acid 
and coenzyme residues of proteins via Michael-type addition: the sulfhydryl group 
of cysteine (CYS) or lipoic acid, the ε-amino group of lysine (LYS), or the 
imidazol function of histidine (HIS).  
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HNE occupies a prominent place in the hierarchy of LPO end-products and 
growing evidence supports it as a (patho)physiological modulator of signal 
transduction, transcriptional regulation, and post-translational modification of 
proteins (Uchida, 2003;Poli et al., 2008). It is found to be involved in many 
diseases where oxidative stress is increased, including atherosclerosis, 
neurodegenerative disorders and cancers (Cerbone et al., 2007;Mattson, 2009). 
The relevance of HNE to joint biology and pathology is now becoming clearer. In 
our previous study, we have reported for the first time that the level of HNE was 
significantly increased in synovial fluids of patients with OA compared to normal 
subjects and in OA chondrocytes and osteoblasts treated with ROS donors 
(Morquette et al., 2006;Shi et al., 2006). These data are consistent with the results 
reported by Grigolo and colleagues, (Grigolo et al., 2003) who found higher levels 
of both malondialdehyde (MDA) and HNE in human OA synoviocytes compared 
to normal cells. Furthermore, we demonstrated that HNE induced transcriptional 
and post-translational modification of Col II and MMP-13, suggesting that HNE 
could play a role in cartilage degradation in OA (Morquette et al., 2006). In 
another study, we have identified two distinct mechanisms of action of HNE in 
OA chondrocytes, which include upregulation of COX-2 via ATF/CREB 
activation and inhibition of iNOS via NF-κB inactivation (Vaillancourt et al., 
2007). In this previous study, we showed that COX-2 expression at protein and 
mRNA levels was detectable within 2 h of incubation with 10 µM of HNE and 
plateaued at 8 h of incubation before declining afterwards. Moreover, we revealed 
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that HNE-induced COX-2 production expression required the activation of p38 
MAPK signaling pathway. Furthermore, overexpression of WT p38 MAPK in OA 
chondrocytes enhanced HNE-induced COX-2 protein expression and promoter 
activity. Interestingly, this induction is specific for HNE since other aldehydes, 
such as acrolein and 2-nonenal, possessing an analogous functionality to HNE 
were all inactive in terms of COX-2 expression in these cells (Kumagai et al., 
2000). 
 
Regulation of COX-2 and mPGES-1 by HNE 
In the present study, we have extended our investigation to evaluate the 
potential role of HNE in inflammatory response in OA. With the ultimate goal of 
clarifying this role, we documented firstly the ability of HNE to modulate COX-2 
and mPGES-1 as well as the production of PGE2, using two types of stimulation: 
single and repeated treatments. We have observed that 10 μM HNE (with one 
treatment) induced PGE2 release as well as COX-2 and mPGES-1 expression at 
protein and mRNA levels and plateaued at 8 h of incubation before declining 
afterwards at 16 and 24 h respectively in OA chondrocytes. These data are in 
concordance with our previously reported COX-2 data and are supported by other 
studies indicating that HNE-induced COX-2 expression and PGE2 release declined 
rapidly in various cell lines, such as rat liver RL34 epithelial cells and RAW264.7 
macrophages (Kumagai et al., 2000;Kumagai et al., 2002;Kumagai et al., 
2004;Vaillancourt et al., 2007). Interestingly, our results indicated that the 
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reductions of COX-2 and mPGES-1 expression at 16 h and 24 h were completely 
abolished by repetitive stimulation of cells with 10 μM HNE (8 treatments at 
regular interval of 2 h), supporting the hypothesis that the decrease of COX-2 and 
mPGES-1 expression is linked to HNE metabolism in chondrocytes. Mammalian 
cells have developed multiple enzymatic pathways for the detoxification of HNE. 
The best characterized of these enzymes include the aldehyde dehydrogenase and 
alcohol dehydrogenase (Esterbauer et al., 1991;Ullrich et al., 1997). The estimated 
half-life of HNE in cells was approximately 1 h (Pizzimenti et al., 2002).  
 
Since the regulation of mPGES-1 by HNE had not yet been reported, we 
extended our investigation to determine whether changes in mRNA levels can be 
ascribed to changes in promoter activity. To do so, human OA chondrocytes were 
transiently transfected with the human mPGES-1 promoter-luciferase reporter 
gene. Treatment of transfected cells with 10 μM HNE at increasing periods of 
incubation led to a time-dependent increase of the mPGES-1 promoter activity. 
These data are consistent with the regulation of mPGES-1 expression by HNE at 
the transcriptional level. The mPGES-1 promoter construct contains several 
proximal regulation sites, such as Egr-1 and NF-κB (Cheng et al., 2004; Ackerman 
et al., 2008). Emerging evidence suggests that the transcriptional induction of 
mPGES-1 by cytokines and growth factors is controlled primarily by Egr-1 
through two Egr-1 binding motifs identified in the proximal promoter region of the 
mPGES-1 region (Cheng et al., 2004). Thus, we hypothesized that induction of 
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Egr-1 activity by HNE could be the mechanism by which HNE exerts its inducer 
effect on mPGES-1 transcription. To gain insight into the mechanism of HNE-
mediated mPGES-1 expression through Egr-1 activation, OA chondrocytes were 
transiently transfected with the synthetic luciferase reporter construct containing 
three tandem repeats of Egr-1 motif. Data showed that HNE induced the 
transcriptional activity of the above construct, suggesting the implication of this 
transcription factor in HNE-induced transcriptional activity of mPGES-1 promoter. 
In our Western blot analysis, we observed that 10 μM HNE increased Egr-1 
protein expression in a time-dependent manner. Recently, ROS were reported to 
enhance Egr-1 expression, which in turn contributes to the elevated level of 
mPGES-1 in inflamed cells (Hasan and Schafer, 2008). Cheng et al. 2004 
examined the role of PPARγ in the regulation of mPGES-1 in OA cartilage; the 
authors showed that PPARγ activation suppresses mPGES-1 expression via 
negative interference with Egr-1. Altogether, this is the first evidence supporting 
that mPGES-1 up-regulation by HNE required Egr-1 transcriptional activity and 
expression in OA chondrocytes.  
 
Regulation of FLAP and 5-LOX by HNE  
FLAP and 5-LOX are two primary enzymes involved in LTB4 biosynthesis. 
Moreover, recent investigations of how FLAP activates 5-LOX propose that 5-
LOX does not actually bind FLAP, but rather that FLAP binds arachidonic acid 
and presents it to 5-LOX in such a manner that 5-LOX becomes fully 
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enzymatically active (Peters-Golden, 1998). The expressions of 5-LOX and FLAP 
have been variably documented in different cells and tissues. Usually, significant 
levels are found in bone marrow-derived cells, such as neutrophils, dendritic cells 
and some lymphocytes but 5-LOX and FLAP levels are not detectable in 
undifferentiated cells (Peters-Golden and Brock, 2003). 5-LOX and FLAP are 
highly enhanced by TGF-β1 and dihydroxyvitamin D3, followed by increased 
production of LTB4 (Brungs et al., 1995;Martel-Pelletier et al., 2004). We 
deciphered the role of HNE in 5-LOX and FLAP expression in order to determine 
the mechanism underlying the modulation of LTB4 biosynthesis in human OA 
chondrocytes.  
 
Our data suggested a potential 5-LOX and FLAP up-regulation by HNE, 
occurring at least in part, at the transcriptional level, as determined by real-time 
quantitative RT-PCR and transient transfection experiments. HNE-induced both 
FLAP and 5-LOX mRNA expression in a time-dependent but different fashion. 
The expression of FLAP is activated earlier than that of 5-LOX, which occurs only 
after 48 hours of HNE stimulation. In the same pattern as 5-LOX expression, HNE 
enhanced LTB4 release after 48 and 72 h of incubation. However, our attempts to 
detect 5-LOX and FLAP protein by Western blot in total cellular protein extracts 
were unsuccessful probably because of their low level as indicated by Martel-
Pelletier et al., 2004. Thereafter, to determine whether the regulation of 5-LOX 
mRNA by HNE occurred at transcriptional level, we carried out transient 
transfection studies. Human OA chondrocytes were transfected with a human 5-
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LOX promoter (–779 to +53) region/luciferase reporter gene construct and 
stimulated with 10 μM HNE at different times of incubation. Data showed that 
HNE increased the luciferase activity of the 5-LOX promoter only after 48 hours 
of incubation. The 5-LOX promoter sequence contains consensus binding sites for 
several transcriptional factors, including Sp1, Egr-1, VDR, NF-κB and AP family 
members. The FLAP promoter sequence contains a TATA box and glucocorticoid 
receptor binding sites (Peters-Golden and Brock, 2003). The investigation of the 
activation of the transcriptional factors associated with these promoters can help us 
to gain insight into how HNE regulates 5-LOX and FLAP expression at 
transcriptional level.  
 
These results were consistent with a previous report of Martel-Pelletier et 
al., 2004 showing that 5-LOX expression is activated in late fashion, leading to the 
late increase in LTB4 production (Martel-Pelletier et al., 2004). The authors 
showed that FLAP mRNA level was significantly enhanced after short period (20 
h) of treatment with TGF-β1 and 1,25-dihydroxyvitamin D3, whereas 5-LOX 
mRNA level increased only after 72 h (Martel-Pelletier et al., 2004). These authors 
suggested that the reason for the late increase in 5-LOX mRNA may be that TGF-
β1 induces only an accumulation of 5-LOX mRNA and not a true up-regulation of 
the gene expression per se. The increase in LTB4 production upon HNE 
stimulation occurred late (48 h) after the beginning of the stimulation. This 
coincided with the time at which the 5-LOX mRNA level was increased and the 
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FLAP gene expression remained high. These data confirm that LTB4 production 
depends on the regulation of both 5-LOX and FLAP. Other studies demonstrated, 
however, that the increase in LTB4 production was related mainly to up-regulation 
of the FLAP gene (Peters-Golden and Brock, 2003) or to a combination with an 
increase in the activity and/or expression of 5-LOX (Steinhilber et al., 
1993;Brungs et al., 1995).  
 
Role of PGE2 and TGF-β1 in 5-LOX and FLAP expression 
PGE2 does not only participate in inflammation by itself, but may also 
regulate the effects of other inflammatory mediators, resulting in greater 
inflammatory and immune responses. Several studies reported that eicosanoid 
products of AA metabolism are important modulators of COX and 5-LOX 
pathways in various types of cells. For example, 5-LOX activity can be inhibited 
by some metabolites of the LOX pathway. PGE2 can inhibit the synthesis of LTB4 
in rat neutrophils and chondrocytes (Ham et al., 1983). Another study showed that 
the expression of mPGES-1 is regulated by PGE2 that may act as an enhancer of 
mPGES-1 in IL-1β stimulated rheumatoid synovial fibroblasts (Kojima et al., 
2003). All these findings help us to better understand how PGE2 and LTB4 induced 
by HNE modulate various cell responses and AA metabolism in OA chondrocytes. 
Several studies showed that both FLAP and 5-LOX expressions were regulated by 
PGE2 (Harizi et al., 2003;Martel-Pelletier et al., 2004). Our results put this 
observation in evidence. PGE2 regulates FLAP and 5-LOX expression in different 
manners. The non-specific inhibitor of COXs naproxen abolishes HNE-induced 
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FLAP expression in OA chondrocytes after 24 and 72 h of incubation. In contrast, 
naproxen stimulates 5-LOX expression compared to unstimulated cells. We 
observed that 5-LOX is expressed only after 72 h of HNE incubation when the 
level of PGE2 was low. This suggests that PGE2 stimulates FLAP expression but 
inhibits 5-LOX expression. Important advances have been made concerning the 
role of PGE2 in metabolism of articular tissues. It was found to be involved not 
only in inflammation responses but may regulate the effects of other inflammatory 
mediators. Therefore, more pharmaceutical companies put their interest in 
mPGES-1, the protein synthesizing PGE2, to treat arthritis due to its inducible 
form and functional link with COX-2 (Fahmi, 2004). In contrast, PGE2 inhibits 5-
LOX after long stimulation time where 5-LOX just starts to be expressed. Our 
results are different than what the group of Harizi had obtained. They observed 
that PGE2 reduces LTB4 release by inhibiting FLAP via IL-10 dependent 
mechanism in dendritic cells, but without any effect on 5-LOX (Harizi et al., 2003). 
This suggests that PGE2 regulates the expression of FLAP and 5-LOX differently 
depending on the types of cells.  
 
The actual therapies to treat OA are limited to reducing the pain in affected 
joints by using either non-selective NSAID or the selective COX-2 drugs. 
Production of both PGE2 and LTB4 requires the existence of arachidonic acid, but 
their synthesis is through different pathways, COX and 5-LOX pathway 
respectively, therefore one of the pathways is favorably to be used depending on 
the condition. Long-term inhibition of COX causes the switch from COX to 5-
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LOX pathway. This is observed in OA patients treated with COX-2 inhibitors 
(Maxis et al., 2006). In our study, we also demonstrated that lower PGE2 
production favors 5-LOX pathway in HNE-treated OA chondrocytes, leading to 
the synthesis of LTB4. However, LTs have greater potential in inflammation 
process and may be more harmful than PGE2 in various tissues due to their 
chemotactic property (Griffiths et al., 1995). For this reason, drugs that can inhibit 
both COX and LOX attract pharmaceutical attention in the treatment of 
inflammatory diseases. Tepoxalin and licofelone (ML3000) are drugs identified to 
have this function (Knight et al., 1996;Paredes et al., 2002). Today, licofelone is in 
phase III clinical development. It does not only lower the production of PGE2 and 
LTB4 but also can modify abnormal bone remodeling in OA; thus it was thought to 
be useful to treat OA (Paredes et al., 2002).   
 
In addition to the involvement of PGE2 in HNE-induced 5-LOX/FLAP, we 
found additional data supporting the role of TGF-β1 in this process. Our findings 
showed that HNE induced TGF-β1 and that TGF-β1 neutralization by using anti- 
TGF-β1 antibody attenuates HNE-induced 5-LOX and FLAP after 72 h of 
incubation. These results suggest that the regulation of 5-LOX/FLAP by HNE is 
mediated partially via TGF-β1 production. Leonarduzzi et al. 1997 were the first 
to demonstrate that HNE induced TGF-β1 production. Furthermore, there are a 
number of reports supporting the role of TGF-β1 in 5-LOX and FLAP expression 
through activation of smad 3/4 (Brungs et al., 1995;Martel-Pelletier et al., 
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2004;Seuter et al., 2006). All these findings suggest that HNE stimulates the 
production of TGF-β1, which probably induces the expression of 5-LOX and 
FLAP through smad 3/4 involvement. 
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High levels of ROS and HNE are present in OA synovial tissues. Our study 
has several important implications and suggests that HNE production in OA 
articular tissues contributes to inflammatory responses in OA. We investigated the 
effect of HNE on the production of inflammatory mediators PGE2 and LTB4 and 
on the expression of COX-2, mPGES-1 and FLAP/5-LOX, the primary enzymes 
responsible for their biosynthesis. HNE induces differently the production of PGE2 
and LTB4. Depletion of PGE2 promotes LTB4 formation, leading to the switch of 
AA metabolism from COX to FLAP/5-LOX pathway. The expression of FLAP 
and mainly 5-LOX increase after HNE stimulation when that of COX-2 and 
mPGES-1 decrease. In addition, the expression of FLAP happens earlier than that 
5-LOX, which induces late biosynthesis of LTB4. Furthermore, PGE2 and TGF-β1 
have regulatory effect on the expression of FLAP and 5-LOX at mRNA level.  
 
A lot of perspectives are given by this study. Activations of certain 
transcriptional factors involved in the regulation of mPGES-1 and 5-LOX by HNE 
remain to be investigated, such as smad 2/3 and VDR for mPGES-1 and 5-LOX 
promoter studies. This will help us to better understand the role of smad 2/3 and 
VDR in mPGES-1 and 5-LOX expression. Also, it will be interesting to study the 
mechanism underlying the switch of pathways in AA metabolism.  
 
Pathogenesis of OA is mainly characterized by inflammatory and catabolic 
process in parallel with high presence of several mediators, including ROS, HNE, 
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NO and PGE2. We gave evidence that HNE stimulates the production of pro-
inflammatory mediators PGE2 and LTB4 in human OA chondrocytes. Importantly, 
these factors do not only provoke inflammatory response but may also be involved 
in cartilage destruction. High concentration of PGE2 can inhibit collagen synthesis 
in differentiated osteoblasts and LTB4 has been identified to be a potent factor that 
induces TNF-α, IL-1β and MMPs. In a pharmaceutical point of view, inhibition of 
both the prostaglandins and LTs biosynthesis pathway is better than single 
interference due to the additive anti-inflammatory effectiveness and lower 
gastrointestinal toxicity. Therefore, a drug that has this effect may become an 
innovative treatment of OA and other inflammatory diseases. This study helps us 
to better understand the regulation of inflammatory factors and primary enzymes 
involved in OA by HNE. 
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